{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:08:06Z","timestamp":1781042886684,"version":"3.54.1"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin. J. Integr. Med."],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11655-024-4203-9","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T08:31:44Z","timestamp":1730190704000},"page":"170-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Research Progress of Chinese Medicine Monomers in Treatment of Cholangiocarcinoma"],"prefix":"10.1007","volume":"31","author":[{"given":"Xiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-lin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"4203_CR1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/hep.31200","volume":"72","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Lawrence N. Insights into the origin of intrahepatic cholangiocarcinoma from mouse models. Hepatology 2020;72:305\u2013314.","journal-title":"Hepatology"},{"key":"4203_CR2","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gregory J. Cholangiocarcinoma. Lancet 2014;383;2168\u20132179.","journal-title":"Lancet"},{"key":"4203_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma. Nat Rev Dis Primers 2021;7:65\u201382.","journal-title":"Nat Rev Dis Primers"},{"key":"4203_CR4","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.aohep.2022.100737","volume":"27","author":"A Elvevi","year":"2022","unstructured":"Elvevi A, Laffusa A, Scaravaglio M, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol 2022;27:100737.","journal-title":"Ann Hepatol"},{"key":"4203_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11655-019-3180-x","volume":"26","author":"XB Sui","year":"2020","unstructured":"Sui XB, Xie T. Combination of Chinese and Western medicine to prevent and reverse resistance of cancer cells to anticancer drugs. Chin J Integr Med 2020;26:251\u2013255.","journal-title":"Chin J Integr Med"},{"key":"4203_CR6","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s11655-023-3743-8","volume":"29","author":"LJ Xiong","year":"2023","unstructured":"Xiong LJ, Tian YF, Zhai CT, et al. Application and effectiveness of Chinese medicine in regulating immune checkpoint pathways. Chin J Integr Med 2023;29:1045\u20131056.","journal-title":"Chin J Integr Med"},{"key":"4203_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13020-021-00423-4","volume":"16","author":"Z Chen","year":"2021","unstructured":"Chen Z, Lin T, Liao X, et al. Network pharmacology based research into the effect and mechanism of Yinchenhao Decoction against cholangiocarcinoma. Chin Med 2021;16:13\u201333.","journal-title":"Chin Med"},{"key":"4203_CR8","first-page":"1","volume":"26","author":"Y Wang","year":"2020","unstructured":"Wang Y, Dong B, Xue W, et al. Anticancer effect of Radix Astragali on cholangiocarcinoma in vitro and its mechanism via network pharmacology. Med Sci Monit 2020;26:1\u201320.","journal-title":"Med Sci Monit"},{"key":"4203_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13020-019-0270-9","volume":"14","author":"H Luo","year":"2019","unstructured":"Luo H, Vong CT, Chen H, et al. Naturally occurring anticancer compounds: shining from Chinese herbal medicine. Chin Med 2019;14:48\u2013105.","journal-title":"Chin Med"},{"key":"4203_CR10","doi-asserted-by":"publisher","first-page":"109570","DOI":"10.1016\/j.biopha.2019.109570","volume":"121","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang Q, Chen Y, et al. Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomed Pharmacother 2020;121:109570.","journal-title":"Biomed Pharmacother"},{"key":"4203_CR11","doi-asserted-by":"publisher","first-page":"111044","DOI":"10.1016\/j.biopha.2020.111044","volume":"133","author":"K Wang","year":"2021","unstructured":"Wang K, Chen Q, Shao Y, et al. Anticancer activities of TCM and their active components against tumor metastasis. Biomed Pharmacother 2021;133:111044.","journal-title":"Biomed Pharmacother"},{"key":"4203_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","volume":"98","author":"JF Bromberg","year":"1999","unstructured":"Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295\u2013303.","journal-title":"Cell"},{"key":"4203_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1074\/mcp.M114.044404","volume":"14","author":"LL Jin","year":"2015","unstructured":"Jin LL, Wybenga-Groot LE, Tong J, et al. Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity. Mol Cell Proteomics 2015;14:695\u2013706.","journal-title":"Mol Cell Proteomics"},{"key":"4203_CR14","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3892\/ijo.2014.2259","volume":"44","author":"SW Wang","year":"2014","unstructured":"Wang SW, Sun YM. The IL-6\/JAK\/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol 2014;44:1032\u20131040.","journal-title":"Int J Oncol"},{"key":"4203_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3892\/mmr.2022.12687","volume":"25","author":"R Yang","year":"2022","unstructured":"Yang R, Song Y, Shakoor K, et al. Insights into the role of STAT3 in intrahepatic cholangiocarcinoma. Mol Med Rep 2022;25:171\u2013179.","journal-title":"Mol Med Rep"},{"key":"4203_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 2023;22:138\u2013175.","journal-title":"Mol Cancer"},{"key":"4203_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","volume":"21","author":"GY Liu","year":"2020","unstructured":"Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol 2020;21:183\u2013203.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4203_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ctrv.2018.11.001","volume":"72","author":"F Corti","year":"2019","unstructured":"Corti F, Nichetti F, Raimondi A, et al. Targeting the PI3K\/AKT\/mTOR pathway in biliary tract cancers: a review of current evidences and future perspectives. Cancer Treat Rev 2019;72:45\u201355.","journal-title":"Cancer Treat Rev"},{"key":"4203_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0095219","volume":"9","author":"A Ocana","year":"2014","unstructured":"Ocana A, Vera-Badillo F, Al-Mubarak M, et al. Activation of the PI3K\/mTOR\/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS One 2014;9:1\u20138.","journal-title":"PLoS One"},{"key":"4203_CR20","first-page":"4426","volume":"14","author":"Z Wu","year":"2022","unstructured":"Wu Z, Yu X, Zhang S, et al. The role of PI3K\/AKT signaling pathway in gallbladder carcinoma. Am J Transl Res 2022;14:4426\u20134442.","journal-title":"Am J Transl Res"},{"key":"4203_CR21","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1053\/j.gastro.2015.02.056","volume":"148","author":"SP Monga","year":"2015","unstructured":"Monga SP. \u03b2-Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology 2015;148:1294\u20131310.","journal-title":"Gastroenterology"},{"key":"4203_CR22","doi-asserted-by":"publisher","first-page":"1367364","DOI":"10.3389\/fonc.2024.1367364","volume":"14","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Cui T, Wei F, et al. Wnt\/\u03b2-Catenin signaling pathway in hepatocellular carcinoma: pathogenic role and therapeutic target. Front Oncol 2024;14:1367364.","journal-title":"Front Oncol"},{"key":"4203_CR23","doi-asserted-by":"publisher","first-page":"BSR20193353","DOI":"10.1042\/BSR20193353","volume":"40","author":"GF Zhang","year":"2020","unstructured":"Zhang GF, Qiu L, Yang SL, et al. Wnt\/\u03b2-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma. Biosci Rep 2020;40:BSR20193353.","journal-title":"Biosci Rep"},{"key":"4203_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12876-023-02911-3","volume":"23","author":"H Cheng","year":"2023","unstructured":"Cheng H, Li Q. Sevoflurane inhibits cholangiocarcinoma via Wnt\/\u03b2-catenin signaling pathway. BMC Gastroenterol 2023;23:279\u2013288.","journal-title":"BMC Gastroenterol"},{"key":"4203_CR25","doi-asserted-by":"publisher","first-page":"127627","DOI":"10.1016\/j.ijbiomac.2023.127627","volume":"254","author":"H Yang","year":"2024","unstructured":"Yang H, Zhao Y, Song W, et al. The inhibition of \u03b2-catenin activity by luteolin isolated from paulownia flowers leads to growth arrest and apoptosis in cholangiocarcinoma. Int J Biol Macromol 2024;254:127627.","journal-title":"Int J Biol Macromol"},{"key":"4203_CR26","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1186\/s12967-023-04613-6","volume":"21","author":"H Zhang","year":"2023","unstructured":"Zhang H, Dong X, Ding X, et al. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt\/\u03b2-catenin signal pathway. J Transl Med 2023;21:900\u2013920.","journal-title":"J Transl Med"},{"key":"4203_CR27","doi-asserted-by":"publisher","first-page":"10037","DOI":"10.3390\/ijms231710037","volume":"23","author":"A Fukushi","year":"2022","unstructured":"Fukushi A, Kim HD, Chang YC, et al. Revisited metabolic control and reprogramming cancers by means of the Warburg effect in tumor cells. Int J Mol Sci 2022;23:10037.","journal-title":"Int J Mol Sci"},{"key":"4203_CR28","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029\u20131033.","journal-title":"Science"},{"key":"4203_CR29","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10555-022-10027-5","volume":"41","author":"BC Jones","year":"2022","unstructured":"Jones BC, Pohlmann PR, Clarke R, et al. Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux. Cancer Metastasis Rev 2022;41:447\u2013458.","journal-title":"Cancer Metastasis Rev"},{"key":"4203_CR30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab 2016;24:657\u2013671.","journal-title":"Cell Metab"},{"key":"4203_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1158\/0008-5472.CAN-14-2260","volume":"75","author":"I Marchiq","year":"2015","unstructured":"Marchiq I, Le Floch R, Roux D, et al. Genetic disruption of lactate\/H+ symporters (MCTs) and their subunit CD147\/Basigin sensitizes glycolytic tumor cells to phenformin. Cancer Res 2015;75:171\u2013180.","journal-title":"Cancer Res"},{"key":"4203_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-020-01629-4","volume":"39","author":"J Feng","year":"2020","unstructured":"Feng J, Li J, Wu L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39:126\u2013145.","journal-title":"J Exp Clin Cancer Res"},{"key":"4203_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1432-1033.1997.00259.x","volume":"246","author":"DG Hardie","year":"1997","unstructured":"Hardie DG, Carling D. The AMP-activated protein kinase\u2014fuel gauge of the mammalian cell? Eur J Biochem 1997;246:259\u2013273.","journal-title":"Eur J Biochem"},{"key":"4203_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature23275","volume":"548","author":"CS Zhang","year":"2017","unstructured":"Zhang CS, Hawley SA, Zong Y, et al. Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK. Nature 2017;548:112\u2013116.","journal-title":"Nature"},{"key":"4203_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmet.2016.09.003","volume":"24","author":"CS Zhang","year":"2016","unstructured":"Zhang CS, Li M, Ma T, et al. Metformin activates AMPK through the lysosomal pathway. Cell Metab 2016;24:521\u2013522.","journal-title":"Cell Metab"},{"key":"4203_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","volume":"21","author":"GY Liu","year":"2020","unstructured":"Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol 2020;21:183\u2013203.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4203_CR37","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","volume":"30","author":"DM Gwinn","year":"2008","unstructured":"Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008;30:214\u2013226.","journal-title":"Mol Cell"},{"key":"4203_CR38","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1074\/jbc.M114.622571","volume":"290","author":"S Mukhopadhyay","year":"2015","unstructured":"Mukhopadhyay S, Saqcena M, Chatterjee A, et al. Reciprocal regulation of AMP-activated protein kinase and phospholipase D. J Biol Chem 2015;290:6986\u20136993.","journal-title":"J Biol Chem"},{"key":"4203_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011;13:132\u2013141.","journal-title":"Nat Cell Biol"},{"key":"4203_CR40","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cell.2012.12.016","volume":"152","author":"J Kim","year":"2013","unstructured":"Kim J, Kim YC, Fang C, et al. Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. Cell 2013;152:290\u2013303.","journal-title":"Cell"},{"key":"4203_CR41","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.7150\/jca.62779","volume":"12","author":"Q Wu","year":"2021","unstructured":"Wu Q, Li D, Sun T, et al. Bai-He-Gu-Jin-Tang formula suppresses lung cancer via AKT\/GSK3\u03b2\/\u03b2-catenin and induces autophagy via the AMPK\/mTORC1\/ULK1 signaling pathway. J Cancer 2021;12:6576\u20136587.","journal-title":"J Cancer"},{"key":"4203_CR42","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10517-022-05550-y","volume":"173","author":"M Jia","year":"2022","unstructured":"Jia M, Yang F, Xu Y, et al. Baicalin induced apoptosis of human cholangiocarcinoma cell through activating AMPK\/mTORC1\/p70S6K signaling pathway. Bull Exp Biol Med 2022;173:366\u2013370.","journal-title":"Bull Exp Biol Med"},{"key":"4203_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol 2022;23:74\u201388.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4203_CR44","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3390\/cells9122675","volume":"9","author":"L Stolarova","year":"2020","unstructured":"Stolarova L, Kleiblova P, Janatova M, et al. CHEK2 germline variants in cancer predisposition: stalemate rather than checkmate. Cells 2020;9:2675\u20132717.","journal-title":"Cells"},{"key":"4203_CR45","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41580-021-00394-2","volume":"22","author":"JH Lee","year":"2021","unstructured":"Lee JH, Paull TT. Cellular functions of the protein kinase ATM and their relevance to human disease. Nat Rev Mol Cell Biol 2021;22:796\u2013814.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4203_CR46","doi-asserted-by":"publisher","first-page":"982961","DOI":"10.3389\/fonc.2022.982961","volume":"12","author":"Z Xia","year":"2022","unstructured":"Xia Z, Li M, Hu M, et al. Phosphoproteomics reveals that cinobufotalin promotes intrahepatic cholangiocarcinoma cell apoptosis by activating the ATM\/CHK2\/p53 signaling pathway. Front Oncol 2022;12:982961.","journal-title":"Front Oncol"},{"key":"4203_CR47","doi-asserted-by":"publisher","first-page":"50747","DOI":"10.18632\/oncotarget.17096","volume":"8","author":"A Hu","year":"2017","unstructured":"Hu A, Huang JJ, Zhang JF, et al. Curcumin induces G2\/M cell cycle arrest and apoptosis of head and neck squamous cell carcinoma in vitro and in vivo through ATM\/Chk2\/p53-dependent pathway. Oncotarget 2017;8:50747\u201350760.","journal-title":"Oncotarget"},{"key":"4203_CR48","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.3390\/molecules26113374","volume":"26","author":"S Bhambhani","year":"2021","unstructured":"Bhambhani S, Kondhare KR, Giri AP. Diversity in chemical structures and biological properties of plant alkaloids. Molecules 2021;26:3374\u20133403.","journal-title":"Molecules"},{"key":"4203_CR49","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.3390\/molecules28145578","volume":"28","author":"K Olofinsan","year":"2023","unstructured":"Olofinsan K, Abrahamse H, George BP. Therapeutic role of alkaloids and alkaloid derivatives in cancer management. Molecules 2023;28:5578\u20135596.","journal-title":"Molecules"},{"key":"4203_CR50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1389557521666210712111331","volume":"22","author":"A Patel","year":"2022","unstructured":"Patel A, Vanecha R, Patel J, et al. Development of natural bioactive alkaloids: anticancer perspective. Mini Rev Med Chem 2022;22:200\u2013212.","journal-title":"Mini Rev Med Chem"},{"key":"4203_CR51","first-page":"6329","volume":"15","author":"X Zhang","year":"2018","unstructured":"Zhang X, Yan Z, Xu T, et al. Solamargine derived from Solanum nigrum induces apoptosis of human cholangiocarcinoma QBC939 cells. Oncol Lett 2018;15:6329\u20136335.","journal-title":"Oncol Lett"},{"key":"4203_CR52","first-page":"364625","volume":"2014","author":"WY Lee","year":"2014","unstructured":"Lee WY, Chen KC, Chen HY, et al. Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers. Biomed Res Int 2014;2014:364625.","journal-title":"Biomed Res Int"},{"key":"4203_CR53","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.biocel.2019.01.012","volume":"108","author":"B Zhu","year":"2019","unstructured":"Zhu B, Zhao L, Liu Y, et al. Induction of phosphatase shatterproof 2 by evodiamine suppresses the proliferation and invasion of human cholangiocarcinoma. Int J Biochem Cell Biol 2019;108:98\u2013110.","journal-title":"Int J Biochem Cell Biol"},{"key":"4203_CR54","first-page":"1297","volume":"35","author":"YQ Qu","year":"2023","unstructured":"Qu YQ, Zhang QY, Tan XY, et al. Effect of nuciferine against the proliferation of cholangiocarcinoma cells through Akt\/mTOR\/4EBP1-glycolytic pathway. Nat Product Res Develop (Chin) 2023;35:1297\u20131304.","journal-title":"Nat Product Res Develop (Chin)"},{"key":"4203_CR55","series-title":"Dissertation","volume-title":"Research on the mechanism of lysicamine hydrochloride inhibiting intrahepatic cholangiocarcinoma","author":"S Peng","year":"2019","unstructured":"Peng S. Research on the mechanism of lysicamine hydrochloride inhibiting intrahepatic cholangiocarcinoma. [Dissertation]. Guangzhou: Guangzhou University of Chinese Medicine;2019."},{"key":"4203_CR56","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1124\/jpet.119.263202","volume":"373","author":"T Liu","year":"2020","unstructured":"Liu T, Zhu G, Yan W, et al. Cordycepin inhibits cancer cell proliferation and angiogenesis through a DEK interaction via ERK signaling in cholangiocarcinoma. J Pharmacol Exp Ther 2020;373:279\u2013289.","journal-title":"J Pharmacol Exp Ther"},{"key":"4203_CR57","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.3390\/molecules26195973","volume":"26","author":"S Panwong","year":"2021","unstructured":"Panwong S, Wathikthinnakon M, Kaewkod T, et al. Cordycepin sensitizes cholangiocarcinoma cells to be killed by natural killer-92 (NK-92) cells. Molecules 2021;26:5973.","journal-title":"Molecules"},{"key":"4203_CR58","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.7150\/ijbs.67476","volume":"18","author":"R Hou","year":"2022","unstructured":"Hou R, Li Y, Luo X, et al. ENKUR expression induced by chemically synthesized cinobufotalin suppresses malignant activities of hepatocellular carcinoma by modulating \u03b2-catenin\/c-Jun\/MYH9\/USP7\/c-Myc axis. Int J Biol Sci 2022;18:2553\u20132567.","journal-title":"Int J Biol Sci"},{"key":"4203_CR59","doi-asserted-by":"publisher","first-page":"174280","DOI":"10.1016\/j.ejphar.2021.174280","volume":"906","author":"H Meng","year":"2021","unstructured":"Meng H, Shen M, Li J, et al. Novel SREBP1 inhibitor cinobufotalin suppresses proliferation of hepatocellular carcinoma by targeting lipogenesis. Eur J Pharmacol 2021;906:174280.","journal-title":"Eur J Pharmacol"},{"key":"4203_CR60","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.2174\/1389557521666210112143024","volume":"21","author":"B Chopra","year":"2021","unstructured":"Chopra B, Dhingra AK, Dhar KL, et al. Emerging role of terpenoids for the treatment of cancer: a review. Mini Rev Med Chem 2021;21:2300\u20132336.","journal-title":"Mini Rev Med Chem"},{"key":"4203_CR61","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/molecules28010272","volume":"28","author":"P Yao","year":"2022","unstructured":"Yao P, Liu Y. Terpenoids: natural compounds for nonalcoholic fatty liver disease (NAFLD) therapy. Molecules 2022;28:272\u2013309.","journal-title":"Molecules"},{"key":"4203_CR62","doi-asserted-by":"publisher","first-page":"111332","DOI":"10.1016\/j.biopha.2021.111332","volume":"137","author":"H Li","year":"2021","unstructured":"Li H, Gao C, Liu C, et al. A review of the biological activity and pharmacology of cryptotanshinone, an important active constituent in Danshen. Biomed Pharmacother 2021;137:111332.","journal-title":"Biomed Pharmacother"},{"key":"4203_CR63","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.2147\/DDDT.S132488","volume":"11","author":"F Ke","year":"2017","unstructured":"Ke F, Wang Z, Song X, et al. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2\/STAT3 and PI3K\/Akt\/NF \u03ba B pathways in cholangiocarcinoma cells. Drug Des Devel Ther 2017;11:1753\u20131766.","journal-title":"Drug Des Devel Ther"},{"key":"4203_CR64","first-page":"805","volume":"50","author":"G Zhou","year":"2020","unstructured":"Zhou G, Wang J, Chen Y, et al. Cryptotanshinone enhances sensitivity of cholangiocarcinoma cells to gemcitabine chemotherapy. J Wenzhou Med Univ (Chin) 2020;50:805\u2013809.","journal-title":"J Wenzhou Med Univ (Chin)"},{"key":"4203_CR65","doi-asserted-by":"publisher","first-page":"771418","DOI":"10.3389\/fonc.2022.771418","volume":"12","author":"A Massa","year":"2022","unstructured":"Massa A, Peraldo-Neia C, Vita F, et al. Paclitaxel restores sensitivity to chemotherapy in preclinical models of multidrug-resistant intrahepatic cholangiocarcinoma. Front Oncol 2022;12:771418.","journal-title":"Front Oncol"},{"key":"4203_CR66","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11655-018-2847-z","volume":"25","author":"YM Wei","year":"2019","unstructured":"Wei YM, Wang YH, Xue HQ, et al. Triptolide, a potential autophagy modulator. Chin J Integr Med 2019;25:233\u2013240.","journal-title":"Chin J Integr Med"},{"key":"4203_CR67","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/1471-2407-14-271","volume":"14","author":"X Ding","year":"2014","unstructured":"Ding X, Zhang B, Pei Q, et al. Triptolide induces apoptotic cell death of human cholangiocarcinoma cells through inhibition of myeloid cell leukemia-1. BMC Cancer 2014;14:271\u2013281.","journal-title":"BMC Cancer"},{"key":"4203_CR68","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jss.2010.03.067","volume":"163","author":"KA Clawson","year":"2010","unstructured":"Clawson KA, Borja-Cacho D, Antonoff MB, et al. Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma. J Surg Res 2010;163:244\u2013249.","journal-title":"J Surg Res"},{"key":"4203_CR69","doi-asserted-by":"publisher","first-page":"154575","DOI":"10.1016\/j.phymed.2022.154575","volume":"109","author":"L Li","year":"2023","unstructured":"Li L, Wang C, Qiu Z, et al. Triptolide inhibits intrahepatic cholangiocarcinoma growth by suppressing glycolysis via the AKT\/mTOR pathway. Phytomedicine 2023;109:154575.","journal-title":"Phytomedicine"},{"key":"4203_CR70","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/cam4.2719","volume":"9","author":"B Zhu","year":"2020","unstructured":"Zhu B, Wei Y. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN\/PI3K\/Akt pathway. Cancer Med 2020;9:783\u2013796.","journal-title":"Cancer Med"},{"key":"4203_CR71","doi-asserted-by":"publisher","first-page":"722331","DOI":"10.3389\/fonc.2021.722331","volume":"11","author":"R Yu","year":"2021","unstructured":"Yu R, Jin G, Fujimoto M. Dihydroartemisinin: a potential drug for the treatment of malignancies and inflammatory diseases. Front Oncol 2021;11:722331.","journal-title":"Front Oncol"},{"key":"4203_CR72","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/mc.22893","volume":"57","author":"S Thongchot","year":"2018","unstructured":"Thongchot S, Vidoni C, Ferraresi A, et al. Dihydroartemisinin induces apoptosis and autophagy-dependent cell death in cholangiocarcinoma through a DAPK1-BECLIN1 pathway. Mol Carcinog 2018;57:1735\u20131750.","journal-title":"Mol Carcinog"},{"key":"4203_CR73","first-page":"345","volume":"33","author":"S Xiang","year":"2017","unstructured":"Xiang S, Shao Z, Zhu J, et al. Study on the inhibitory effect of dihydroartemisinin on transplanted tumor of human cholangiocarcinoma in nude mice. J Pract Tradit Chin Med (Chin) 2017;33:345\u2013346.","journal-title":"J Pract Tradit Chin Med (Chin)"},{"key":"4203_CR74","first-page":"4","volume":"26","author":"Z Shao","year":"2016","unstructured":"Shao Z, Xiang S, Zhu J, et al. Experimental study on the treatment of cholangiocarcinoma with dihydroartemisinin combined with gemcitabine. Shenzhen J Integr Tradit Chin West Med (Chin) 2016;26:4\u20136.","journal-title":"Shenzhen J Integr Tradit Chin West Med (Chin)"},{"key":"4203_CR75","doi-asserted-by":"publisher","first-page":"13123","DOI":"10.1007\/s00432-023-05188-x","volume":"149","author":"W Chen","year":"2023","unstructured":"Chen W, Liu Q, Huang Z, et al. Cucurbitacin C as an effective anti-cancer agent: unveiling its potential role against cholangiocarcinoma and mechanistic insights. J Cancer Res Clin Oncol 2023;149:13123\u201313136.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4203_CR76","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00210-018-1584-3","volume":"392","author":"S Klungsaeng","year":"2019","unstructured":"Klungsaeng S, Kukongviriyapan V, Prawan A, et al. Cucurbitacin B induces mitochondrial-mediated apoptosis pathway in cholangiocarcinoma cells via suppressing focal adhesion kinase signaling. Naunyn Schmiedebergs Arch Pharmacol 2019;392:271\u2013278.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4203_CR77","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1142\/S0192415X2050072X","volume":"48","author":"S Klungsaeng","year":"2020","unstructured":"Klungsaeng S, Kukongviriyapan V, Prawan A, et al. Targeted modulation of FAK\/PI3K\/PDK1\/AKT and FAK\/p53 pathways by cucurbitacin B for the antiproliferation effect against human cholangiocarcinoma Cells. Am J Chin Med 2020;48:1475\u20131489.","journal-title":"Am J Chin Med"},{"key":"4203_CR78","doi-asserted-by":"publisher","first-page":"153473542211248","DOI":"10.1177\/15347354221124861","volume":"21","author":"P Kaewmeesri","year":"2022","unstructured":"Kaewmeesri P, Pocasap P, Kukongviriyapan V, et al. Anti-metastatic potential of natural triterpenoid cucurbitacin b against cholangiocarcinoma cells by targeting SRC protein. Integr Cancer Ther 2022;21:15347354221124861.","journal-title":"Integr Cancer Ther"},{"key":"4203_CR79","first-page":"74","volume":"28","author":"L Li","year":"2022","unstructured":"Li L, Deng D, Tan X, et al. Mechanism of cucurbitacin B in regulating glycolysis and inhibiting proliferation of HuCCT1 cells. Chin J Exp Med Formul (Chin) 2022;28:74\u201381.","journal-title":"Chin J Exp Med Formul (Chin)"},{"key":"4203_CR80","doi-asserted-by":"publisher","first-page":"108812","DOI":"10.1016\/j.biopha.2019.108812","volume":"114","author":"B Zhai","year":"2019","unstructured":"Zhai B, Zhang N, Han X, et al. Molecular targets of \u03b2-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: a review. Biomed Pharmacother 2019;114:108812.","journal-title":"Biomed Pharmacother"},{"key":"4203_CR81","doi-asserted-by":"publisher","first-page":"874457","DOI":"10.3389\/fonc.2022.874457","volume":"12","author":"Q Wu","year":"2022","unstructured":"Wu Q, Shi X, Pan Y, et al. The chemopreventive role of \u03b2-elemene in cholangiocarcinoma by restoring PCDH9 expression. Front Oncol 2022;12:874457.","journal-title":"Front Oncol"},{"key":"4203_CR82","first-page":"814","volume":"20","author":"X Liu","year":"2022","unstructured":"Liu X, Wang X. Recent advances on the structural modification of parthenolide and its derivatives as anticancer agents. Chin J Nat Med 2022;20:814\u2013829.","journal-title":"Chin J Nat Med"},{"key":"4203_CR83","doi-asserted-by":"publisher","first-page":"118075","DOI":"10.1016\/j.jep.2024.118075","volume":"328","author":"Y He","year":"2024","unstructured":"He Y, Yu Q, Ma X, et al. A metabolomics approach reveals metabolic disturbance of human cholangiocarcinoma cells after parthenolide treatment. J Ethnopharmacol 2024;328:118075.","journal-title":"J Ethnopharmacol"},{"key":"4203_CR84","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s11655-022-3674-9","volume":"29","author":"GV de Sousa Silva","year":"2023","unstructured":"de Sousa Silva GV, Lopes ALVFG, Viali IC, et al. Therapeutic properties of flavonoids in treatment of cancer through autophagic modulation: a systematic review. Chin J Integr Med 2023;29:268\u2013279.","journal-title":"Chin J Integr Med"},{"key":"4203_CR85","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2174\/1568026622666220308162049","volume":"22","author":"ZG Zhou","year":"2022","unstructured":"Zhou ZG, Li DD, Chen Y, et al. Discussion on the structural modification and anti-tumor activity of flavonoids. Curr Top Med Chem 2022;22:561\u2013577.","journal-title":"Curr Top Med Chem"},{"key":"4203_CR86","doi-asserted-by":"publisher","first-page":"11042","DOI":"10.3390\/ijms231911042","volume":"23","author":"Y Gu","year":"2022","unstructured":"Gu Y, Zheng Q, Fan G, et al. Advances in anti-cancer activities of flavonoids in Scutellariae Radix: perspectives on mechanism. Int J Mol Sci 2022;23:11042.","journal-title":"Int J Mol Sci"},{"key":"4203_CR87","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ctrv.2008.09.005","volume":"35","author":"M Li-Weber","year":"2009","unstructured":"Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents wogonin, baicalein and baicalin. Cancer Treat Rev 2009;35:57\u201368.","journal-title":"Cancer Treat Rev"},{"key":"4203_CR88","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1002\/ptr.7386","volume":"36","author":"K Banik","year":"2022","unstructured":"Banik K, Khatoon E, Harsha C, et al. Wogonin and its analogs for the prevention and treatment of cancer: a systematic review. Phytother Res 2022;36:1854\u20131883.","journal-title":"Phytother Res"},{"key":"4203_CR89","series-title":"Dissertation","volume-title":"Inhibitory effect and mechanism of baicalin on cholangiocarcinoma cells","author":"Y Xu","year":"2020","unstructured":"Xu Y. Inhibitory effect and mechanism of baicalin on cholangiocarcinoma cells [Dissertation]. Chongqing: Southwest Medical University;2020."},{"key":"4203_CR90","first-page":"1404","volume":"55","author":"H He","year":"2023","unstructured":"He H, Guo J, Hu Y, et al. Saikosaponin D reverses epinephrine- and norepinephrine-induced gemcitabine resistance in intrahepatic cholangiocarcinoma by downregulating ADRB2\/glycolysis signaling. Acta Biochim Biophys Sin 2023;55:1404\u20131414.","journal-title":"Acta Biochim Biophys Sin"},{"key":"4203_CR91","series-title":"Dissertation","volume-title":"Preliminary study on the anti-cholangiocarcinoma effect and mechanism of ginsenoside Rh2 in vitro","author":"R Zhao","year":"2023","unstructured":"Zhao R. Preliminary study on the anti-cholangiocarcinoma effect and mechanism of ginsenoside Rh2 in vitro. [Dissertation]. Changchun: Jilin Agriculture University;2023."},{"key":"4203_CR92","series-title":"Dissertation","volume-title":"Experimental study on reversal of multidrug resistance in human cholangiocarcinoma cells by ginsenoside Rg3","author":"H Ma","year":"2019","unstructured":"Ma H. Experimental study on reversal of multidrug resistance in human cholangiocarcinoma cells by ginsenoside Rg3 [Dissertation]. Taiyuan: Shanxi University of Chinese Medicine;2019."},{"key":"4203_CR93","doi-asserted-by":"publisher","first-page":"963689720979162","DOI":"10.1177\/0963689720979162","volume":"30","author":"C Liu","year":"2021","unstructured":"Liu C, Xuan LQ, Li K, et al. Shikonin inhibits cholangiocarcinoma cell line QBC939 by regulating apoptosis, proliferation, and invasion. Cell Transplant 2021;30:963689720979162.","journal-title":"Cell Transplant"},{"key":"4203_CR94","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.21873\/anticanres.14515","volume":"40","author":"U Thonsri","year":"2020","unstructured":"Thonsri U, Seubwai W, Waraasawapati S, et al. Antitumor effect of shikonin, a PKM2 inhibitor, in cholangiocarcinoma cell lines. Anticancer Res 2020;40:5115\u20135124.","journal-title":"Anticancer Res"},{"key":"4203_CR95","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3390\/molecules29061320","volume":"29","author":"WH Talib","year":"2024","unstructured":"Talib WH, Baban MM, Azzam AO, et al. Allicin and cancer hallmarks. Molecules 2024;29:1320\u20131340.","journal-title":"Molecules"},{"key":"4203_CR96","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1159\/000490019","volume":"47","author":"H Chen","year":"2018","unstructured":"Chen H, Zhu B, Zhao L, et al. Allicin inhibits proliferation and invasion in vitro and in vivo via SHP-1-mediated STAT3 signaling in cholangiocarcinoma. Cell Physiol Biochem 2018;47:641\u2013653.","journal-title":"Cell Physiol Biochem"},{"key":"4203_CR97","series-title":"Dissertation","volume-title":"Study on the effect of allicin on epithelial-mesenchymal transition in cholangiocarcinoma cells","author":"S Zheng","year":"2019","unstructured":"Zheng S. Study on the effect of allicin on epithelial-mesenchymal transition in cholangiocarcinoma cells [Dissertation]. Nanjing: Nanjing University of Chinese Medicine;2019."},{"key":"4203_CR98","doi-asserted-by":"publisher","first-page":"835","DOI":"10.5604\/01.3001.0010.5273","volume":"16","author":"RW Hu","year":"2017","unstructured":"Hu RW, Carey EJ, Lindor KD, et al. Curcumin in hepatobiliary disease: pharmacotherapeutic properties and emerging potential clinical applications. Ann Hepatol 2017;16:835\u2013841.","journal-title":"Ann Hepatol"},{"key":"4203_CR99","doi-asserted-by":"publisher","first-page":"e03255","DOI":"10.1016\/j.heliyon.2020.e03255","volume":"6","author":"TT San","year":"2020","unstructured":"San TT, Khaenam P, Prachayasittikul V, et al. Curcumin enhances chemotherapeutic effects and suppresses ANGPTL4 in anoikis-resistant cholangiocarcinoma cells. Heliyon 2020;6:e03255.","journal-title":"Heliyon"},{"key":"4203_CR100","doi-asserted-by":"publisher","first-page":"2162807","DOI":"10.1080\/15384047.2022.2162807","volume":"24","author":"M Chen","year":"2023","unstructured":"Chen M, Qian C, Jin B, et al. Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma. Cancer Biol Ther 2023;24:2162807.","journal-title":"Cancer Biol Ther"},{"key":"4203_CR101","series-title":"Dissertation","volume-title":"Experimental study on reversal of multidrug resistance in human cholangiocarcinoma cells by curcumin combined with verapamil","author":"X Liu","year":"2020","unstructured":"Liu X. Experimental study on reversal of multidrug resistance in human cholangiocarcinoma cells by curcumin combined with verapamil [Dissertation]. Taiyuan: Shanxi University of Chinese Medicine;2020."},{"key":"4203_CR102","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/1568026623666221128144258","volume":"23","author":"J Wang","year":"2023","unstructured":"Wang J, Feng X, Li Z, et al. The flavonoid components of Scutellaria Baicalensis: biopharmaceutical properties and their improvement using nanoformulation techniques. Curr Top Med Chem 2023;23:17\u201329.","journal-title":"Curr Top Med Chem"},{"key":"4203_CR103","first-page":"566","volume":"16","author":"PM Chang","year":"2018","unstructured":"Chang PM, Cheng CT, Wu RC, et al. Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. Oncol Lett 2018;16:566\u2013572.","journal-title":"Oncol Lett"},{"key":"4203_CR104","doi-asserted-by":"publisher","first-page":"114135","DOI":"10.1016\/j.biopha.2022.114135","volume":"158","author":"C Liu","year":"2023","unstructured":"Liu C, Wu K, Li J, et al. Nanoparticle-mediated therapeutic management in cholangiocarcinoma drug targeting: current progress and future prospects. Biomed Pharmacother 2023;158:114135.","journal-title":"Biomed Pharmacother"},{"key":"4203_CR105","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s11655-020-3280-7","volume":"26","author":"HY Yu","year":"2020","unstructured":"Yu HY, Wang XQ, Zhang Y, et al. Application status of Chinese medicine on cancer rehabilitation: a preliminary questionnaire survey. Chin J Integr Med 2020;26:890\u2013896.","journal-title":"Chin J Integr Med"},{"key":"4203_CR106","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/jamaoncol.2018.3277","volume":"4","author":"V Sahai","year":"2018","unstructured":"Sahai V, Catalano PJ, Zalupski MM, et al. Nab-Paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2018;4:1707\u20131712.","journal-title":"JAMA Oncol"}],"container-title":["Chinese Journal of Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-024-4203-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11655-024-4203-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-024-4203-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T02:39:52Z","timestamp":1737772792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11655-024-4203-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["4203"],"URL":"https:\/\/doi.org\/10.1007\/s11655-024-4203-9","relation":{},"ISSN":["1672-0415","1993-0402"],"issn-type":[{"value":"1672-0415","type":"print"},{"value":"1993-0402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"16 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}